GSK moves mRNA flu vaccine to late-stage trials following positive outcomes

Retrieved on: 2024-09-12 18:02:08

Tags for this article:

Click the tags to see associated articles and topics

GSK moves mRNA flu vaccine to late-stage trials following positive outcomes. View article details on hiswai:

Excerpt

In July, GSK bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA credentials.

Article found on: www.financialexpress.com